Ciudad Real

Researchers are evaluating the safety and effectiveness of two drugs, eltrekibart and mirikizumab, in adults with moderately to severely active ulcerative colitis (UC). This study is a phase 2 trial lasting about 4 to 5 years, aiming to understand how well these treatments work alone or together for this chronic condition. Participants will receive either eltrekibart alone, mirikizumab alone, a combination of both, or a placebo. The treatments are administered as drugs, and the study includes a screening period of up to 35 days before enrollment. The total participation time for each person is approximately 69 weeks, which includes the screening and treatment periods. During the trial, participants will be closely monitored to assess the percentage who achieve clinical remission by week 12. Researchers will conduct regular evaluations, which may include medical assessments and questionnaires, to track the safety and effects of the treatments. The study emphasizes careful follow-up to ensure participant safety and to gather detailed information about the therapies over the entire study duration.

Researchers are evaluating patient-reported satisfaction, effectiveness, and safety of subcutaneous Atezolizumab treatment in adults with lung cancer or hepatocellular carcinoma treated in routine clinical practice. This non-interventional, multicenter, multicountry study collects primary data on health-related quality of life and treatment satisfaction for participants receiving Atezolizumab for approved indications. The study focuses on patients with specific lung cancer subtypes and advanced liver cancer who meet defined criteria regarding prior treatments and tumor characteristics. Atezolizumab is given subcutaneously at the discretion of the treating physician independently of study participation. Patients eligible for the study include those with early-stage or metastatic non-small cell lung cancer (NSCLC) with specific PD-L1 expression and genetic profiles, extensive-stage small cell lung cancer (ES-SCLC), and advanced or unresectable hepatocellular carcinoma (HCC) not previously treated with systemic therapy. Treatment administration follows routine clinical practice, with no experimental interventions assigned by the study. Participants complete questionnaires assessing their satisfaction with Atezolizumab treatment and health-related quality of life during cycles 2 and 3 of therapy, each lasting three weeks. The primary outcome measure is the Therapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) score at these cycles. Safety and effectiveness data are monitored as part of routine care. The study collects data on patient experiences to better understand the real-world use of Atezolizumab over the treatment period.

Researchers are evaluating a cloud-based, AI-powered ECG analysis platform called Willem14, designed to detect arrhythmias and abnormal cardiac patterns in high-risk cardiac patients. This multicenter study includes both prospective and retrospective cohorts to assess if the AI can classify and predict arrhythmic episodes at the level of a cardiologist and potentially delay or prevent severe cardiac events like sudden death. Patients included have at least one ECG record in raw data and clinical follow-up data for over one year. The study collects cardiac electrical signals from various medical devices, including in-clinic 12-lead ECGs, telemetries, Holter monitors, wearable ECG devices, and patches for mobile cardiac telemetry. These signals are reviewed by board-certified cardiologists to label arrhythmias and patterns. Participants are randomly divided into two groups: one to train new AI algorithms and another to test the performance of these methods and avoid overfitting. Participants will have their cardiac electrical signals recorded and processed by the AI platform. The study monitors the detection of cardiac arrhythmias and patterns in real-time to 7 minutes. Researchers compare the AI's diagnosis with expert cardiologists' assessments and evaluate model sensitivity, specificity, and accuracy. Informed consent is required, and data quality is closely monitored to ensure valid analysis throughout the study.

Researchers are evaluating the role of Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) with Mitomycin-C in patients with colon cancer that has spread to the peritoneum. The study focuses on patients undergoing complete surgical removal of these metastases combined with systemic chemotherapy. This Phase IV multicenter trial aims to determine if adding HIPEC with Mitomycin-C improves the time patients remain free from cancer recurrence in the peritoneal cavity, addressing limitations seen in previous studies using a different drug and treatment approach. Participants will be divided into two groups: one receiving complete cytoreductive surgery plus HIPEC with Mitomycin-C for 90 minutes, and the other undergoing surgery alone without HIPEC. The HIPEC procedure uses a dose of 35 mg/m2 Mitomycin-C delivered in a heated solution for 90 minutes with specific dose fractionation at set intervals. Only patients with limited volume peritoneal metastases, complete tumor removal, and colon (not rectal) cancer are included. Systemic chemotherapy is given before and/or after surgery as part of the treatment. During the study, patients will be closely monitored to confirm complete tumor removal and disease extent. Researchers will track peritoneal recurrence-free survival over three years as the primary outcome. Patients undergo assessments to ensure they meet health and surgical risk criteria before enrollment. Safety and disease progression are also regularly evaluated, with informed consent and ongoing follow-up care provided throughout the trial.

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are evaluating the Coroflex4 ISAR NEO coronary stent system, a sirolimus-eluting stent, in patients with coronary artery disease and ischemic heart disease. This international, multicenter, prospective, non-randomized post-market clinical follow-up study aims to confirm and support the device's clinical safety and performance in a real-world, unselected patient population, following daily clinical practice. The study complies with the European Union Medical Device Regulation requirements for post-market clinical follow-up. The study involves patients who have been treated or planned to be treated with the Coroflex4 ISAR NEO coronary stent system as intended by the manufacturer. The device is used in patients undergoing percutaneous coronary intervention (PCI) following the latest European Society of Cardiology recommendations. Eligible patients have novel lesion lengths of 2-4 mm. The study collects data from consecutive patients treated with the stent to evaluate outcomes in routine clinical settings without randomization. Participants will be monitored for safety and efficacy outcomes, including freedom from target lesion failure within 7 days after treatment. The research team will follow patients' clinical status and device performance as part of standard care. Informed consent is required, and patients will be observed to confirm the stent's safety and effectiveness under everyday medical practice conditions. The study does not specify a maximum age limit and includes adult patients aged 18 and older.

Researchers are conducting an observational, multicenter epidemiological study to collect information from medical records of patients diagnosed with advanced metastatic or unresectable melanoma in Spain. The study focuses on patients with stage III or IV melanoma at their first diagnosis after January 8, 2018, aiming to describe the characteristics of this patient group without applying any experimental treatments. Participants will receive treatments determined by routine clinical practice, with no interventions or changes mandated by the study protocol. Treatment decisions are made independently of study inclusion, and no additional diagnostic or follow-up procedures beyond standard care will be applied. Patients may have received prior treatments at different hospitals, and their information will be updated across centers with appropriate consent. Throughout the study, researchers will gather data from medical records to characterize the patient population and their treatments. The main outcome measure is the sample characteristics at baseline. Patients will be tracked via assigned codes and follow-up is conducted as per usual clinical procedures, with efforts made to maintain updated information when patients transfer between centers. Participation involves consenting to data collection without additional study-related medical procedures.

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy for people aged 12 to 65 who have mild to moderate allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. Participants are sensitized to grass and olive pollen, and the study is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. The study aims to measure combined symptoms and medication scores over 12 months to assess treatment impact. The study includes three groups receiving different treatments: two doses of purified and polymerized allergen extracts from a mixture of grasses and olive pollen (10,000 MG01 + 10,000 T517 and 30,000 MG01 + 10,000 T517) and a placebo group receiving a similar solution without active ingredients. Treatments are administered subcutaneously over one year. The study is double-blinded and controlled to compare safety and efficacy across groups. Participants will be involved for one year, during which they will record their symptoms and medication use via a smartphone app. Researchers will conduct clinical evaluations, skin tests, and measure specific IgE levels to monitor allergic responses. The main outcome is the Combined Symptoms and Medication Score (CSMS) after 12 months. Safety and treatment adherence will be closely monitored throughout the study period.

Researchers are investigating the effects of different doses of dexamethasone, a corticosteroid, in adults with acute hypoxemic respiratory failure (AHRF) caused by infections, including COVID-19. This condition ranges from mild respiratory illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The trial aims to clarify whether moderate doses of dexamethasone reduce mortality more than low doses in patients requiring mechanical ventilation in intensive care units. Participants will be randomly assigned to receive intravenous dexamethasone either at a low dose of 6 mg per day for 10 days or a higher dose regimen of 20 mg per day for 5 days followed by 10 mg per day for another 5 days. This is a randomized, controlled, open-label study conducted across multiple centers in Spain. The study focuses on patients who are mechanically ventilated with confirmed pulmonary or systemic infections causing AHRF or ARDS. During the study, researchers will monitor patients for 60-day mortality as the main outcome and assess the number of days they are free from mechanical ventilation within 28 days. The study follows the intention-to-treat principle, ensuring all randomized patients are analyzed according to their assigned treatment. The trial includes detailed clinical assessments, chest imaging, and oxygenation measurements as part of patient evaluation throughout the treatment period.

Researchers are studying patients with arrhythmia-induced cardiomyopathy (AiC), a condition where a new arrhythmia causes reduced heart function. The study aims to understand the genetic factors involved in AiC and how these genetics might influence the course of the disease. It will compare the presence of genetic mutations in AiC patients with those in other types of cardiomyopathy or the general population, and explore whether genetics affect patient outcomes. This multicenter observational study follows patients suspected of having AiC who undergo rhythm control treatments such as electric cardioversion or catheter ablation. Inclusion requires a left ventricular ejection fraction below 50% without other clear causes besides arrhythmia. Participants will be monitored for one year after treatment, with follow-up visits at 2, 6, and 12 months including electrocardiograms and echocardiograms to assess heart function and remodeling. Genetic testing will be performed during the study to detect cardiomyopathy-related gene variants. Participants will have imaging tests to confirm AiC by showing improvement in ejection fraction over time. Researchers will track rhythm control status, heart remodeling, and clinical events like heart failure or rhythm issues. The main outcome measured is the prevalence of harmful genetic variants in AiC patients compared to others. Secondary outcomes include cardiovascular event rates and their relationship to genetics and AiC status. Follow-up care will follow routine clinical practices at each center.